Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.4352W HIGH $10.82
Volume
5.95 M
Value Traded
15.27 M
Short % Float
-
Days to Cover
7.0
+16.3%Week
+22.98%1 Month
+66.28%3 Month
+70.22%6 Month
-89%5 Year
-96.79%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
911.07 M
EPS (TTM)
-2.24
P/E Ratio
-
Ent. Value
774.72 M
Total Shares
90.59 M
Float Shares
82.00 M
Insiders
9.46%
Institutions
104.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VSTM Catalyst Timeline
Dated clinical, regulatory and corporate events for Verastem, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Verastem, Inc.
572Total events
37Upcoming
153Tier-1 (high impact)
2011 to 2040Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutVS-7375Clinical Data
Initial multi-tumor efficacy and safety data from TARGET-D 101 Phase 1/2
KRAS G12D-mutant advanced solid tumors (mPDAC, mCRC, NSCLC)source ↗
▼Equity OfferingCorporate
Pricing of $250 million underwritten offering of common stock and pre-funded warrants
▲Dose Finding UpdateVS-7375Trial
900 mg QD established as go-forward monotherapy dose
KRAS G12D-mutant solid tumorssource ↗
●Enrollment UpdateVS-7375Trial
900 mg QD dosing ongoing in TARGET-D 202 Phase 2 registration-directed NSCLC trial
advanced non-small cell lung cancer (NSCLC)source ↗
▲Biomarker DataVS-7375Clinical Data
Deep KRAS G12D ctDNA reductions and CA19-9 responses with VS-7375
KRAS G12D-mutant mPDAC and NSCLCsource ↗
▲Safety Data UpdateVS-7375Clinical Data
Updated safety data for VS-7375 monotherapy and combinations
KRAS G12D-driven tumorssource ↗
▲Primary Endpoint MetVS-7375Clinical Data
VS-7375 900 mg QD achieved 41% confirmed ORR in 2L+ PDAC
2L+ pancreatic ductal adenocarcinoma (PDAC)source ↗
▲FDA Feedback ReceivedVS-7375FDA Meeting
FDA alignment reached on VS-7375 Phase 3 design in 1L mPDAC
first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)source ↗
▲Biomarker DataVS-7375Clinical Data
Biomarker data in mPDAC: ctDNA clearance and CA19-9 reduction
KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (mPDAC)source ↗
▲Oral PresentationAvutometinibApprovedPresentation
RAMP 201 molecular profiling and tumor biomarker analysis presented at IGCS 2026
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Poster PresentationAvutometinibApprovedPresentation
RAMP 201 external control arm analysis presented at IGCS 2026
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Additional DataAvutometinibApprovedClinical Data
External control analysis showed higher weighted ORR and statistically significant PFS improvements vs conventional care
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Biomarker DataAvutometinibApprovedClinical Data
RAMP 201 molecular profiling showed ORR of 18% in KRAS/NRAS/BRAF triple wild-type and 22% in NRAS- or BRAF-mutated LGSOC
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲PublicationAvutometinibApprovedPresentation
RAMP 201 two-year results to appear in October 2026 print issue of Gynecologic Oncology
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Safety Data UpdateVS-7375Clinical Data
Updated safety data for VS-7375 monotherapy and combination
KRAS G12D-mutant solid tumorssource ↗
▲PublicationAvutometinibApprovedPresentation
Two-year long-term results from RAMP 201 published online in Gynecologic Oncology
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Dose Finding UpdateVS-7375Trial
VS-7375 600 mg dose level cleared with SoC with no dose-limiting toxicities
1L KRAS G12D adenocarcinoma of the lungsource ↗
▲Debt Royalty FinancingCorporate
Entered non-dilutive royalty financing agreement with Oberland Capital
▲Trial InitiationVS-7375Trial
Initiated Phase 2 registration-directed trial TARGET-D 202 in 2L/3L NSCLC
non-small cell lung cancersource ↗
▲PK PD DataVS-7375Clinical Data
Updated PK data showed 900 mg QD achieves target plasma levels
advanced solid tumorssource ↗
▲First Patient DosedVS-7375Trial
First patient dosed in TARGET-D 203 Phase 2 trial of VS-7375 in KRAS G12D-mutated mCRC
KRAS G12D-mutated metastatic colorectal cancersource ↗
▲Trial InitiationVS-7375Trial
TARGET-D 203 Phase 2 registration-directed trial now enrolling
KRAS G12D-mutated metastatic colorectal cancersource ↗
▲First Patient DosedVS-7375Trial
First patient dosed in TARGET-D 202 NSCLC trial
non-small cell lung cancer (NSCLC)source ↗
▲Trial InitiationVS-7375Trial
Initiation of TARGET-D 203 Phase 2 registration-directed trial of VS-7375 for mCRC
KRAS G12D-mutated metastatic colorectal cancersource ↗
▲First Patient DosedVS-7375Trial
First patient dosed in TARGET-D 202 Phase 2 trial of VS-7375 in NSCLC
KRAS G12D-mutated advanced or metastatic non-small cell lung cancersource ↗
▲Partnership / LicenseVS-7375Corporate
Executed agreement with Erasca to evaluate VS-7375 with ERAS-0015
KRAS G12D mutant solid tumor modelssource ↗
▲Oral PresentationAvutometinibApprovedPresentation
RAMP 201J results presented at Japanese Society of Gynecologic Oncology Annual Meeting
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
▲Milestone PaymentCorporate
Received $15 million milestone payment from Secura for COPIKTRA sales
▲Full ResultsAvutometinibApprovedClinical Data
Positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with chemotherapy in first-line metastatic pancreatic cancer
first-line metastatic pancreatic cancersource ↗
▲Topline ReadoutAvutometinibApprovedClinical Data
Positive updated results from RAMP 205 Phase 1b/2a in first-line metastatic PDAC
first-line metastatic pancreatic ductal carcinoma (PDAC)source ↗
▲First Patient DosedVS-7375Trial
First patient dosed in TARGET-D 201 PDAC trial
pancreatic ductal adenocarcinoma (PDAC)source ↗
◆Oral PresentationVS-7375Presentation
Investor conference call to report updated data and progress
KRAS G12D-mutated solid tumorssource ↗
▲Fast Track DesignationVS-7375Designation
FDA granted Fast Track Designation to VS-7375 for KRAS G12D NSCLC
KRAS G12D-mutated unresectable locally advanced or metastatic NSCLCsource ↗
●Trial InitiationVS-7375Trial
FPI expected in mid-2026 for VS-7375 in 2L+ CRC combination cohorts
KRAS G12D-mutated metastatic colorectal cancersource ↗
▲First Patient DosedVS-7375Trial
First patient dosed in TARGET-D 201 Phase 2 trial of VS-7375 in PDAC
KRAS G12D-mutated advanced or metastatic pancreatic ductal adenocarcinomasource ↗
▲Fast Track DesignationVS-7375Designation
FDA granted Fast Track Designation to VS-7375 for KRAS G12D-mutated NSCLC
KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancersource ↗
●Quarterly UpdateVS-7375Corporate
Clinical update reported in June 2026
pancreatic, lung, and colorectal cancerssource ↗
▲Enrollment CompleteVS-7375Trial
Completed target enrollment in TARGET-D 101 cohorts
PDAC and NSCLC monotherapy cohorts and CRC cetuximab combination cohortssource ↗
●Topline ReadoutAvutometinibApprovedClinical Data
Updated RAMP 205 results in advanced pancreatic cancer
advanced pancreatic cancersource ↗
●Additional DataAvutometinibApprovedClinical Data
Verastem provided updated results on Phase 1/2 RAMP 205 trial in advanced pancreatic cancer
advanced pancreatic cancersource ↗
▲Additional DataAvutometinibApprovedClinical Data
RAMP 201J showed 44% ORR and 94% disease control rate in recurrent LGSOC
recurrent low-grade serous ovarian cancer (LGSOC)source ↗
Past FDA Catalysts and PDUFA Decisions
How VSTM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | avutometinib plus defactinib | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 20%
Micro Cap(rank 132 of 658)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VS-7375 Small moleculeNCT07659795 | Colorectal Cancer | Phase 2 | RECRUITING | 150 | Dec 1, 2028 | ||||||
| VS-7375 Small moleculeNCT07659782 | Non-Small Cell Lung Cancer | Phase 2 | RECRUITING | 105 | Dec 1, 2028 | ||||||
| VS-7375 Small moleculeNCT07020221 | Pancreatic Ductal Adenocarcinoma | Phase 2 | RECRUITING | 801 | Dec 1, 2028 | ||||||
| Avutometinib Small moleculeMarketedNCT06682572 | Low Grade Serous Ovarian Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 286 | Oct 1, 2027 | ||||||
| Avutometinib Small moleculeMarketedNCT04625270 | Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | ACTIVE NOT_RECRUITING | 227 | Dec 1, 2026 | ||||||
| Avutometinib Small moleculeNCT05074810 | Non Small Cell Lung Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 255 | Apr 1, 2027 | ||||||
| Avutometinib Small moleculeNCT05669482 | KRAS Activating Mutation | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Aug 31, 2027 | ||||||
| Duvelisib Small moleculeMarketedNCT04372602 | COVID-19 | Phase 2 | COMPLETED | 75 | Mar 2, 2022 | ||||||
| Defactinib Small moleculeMarketedNCT01778803 | Ovarian Cancer | Phase 1 | COMPLETED | 112 | Feb 23, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every VSTM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VS-7375 Fast Track | advanced KRAS G12D-mutant cancers | Phase 1/2 | 2026-10-14 | 50% confirmed ORR in 2L pancreatic ductal adenocarcinoma; 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma patient population; 36% confirmed ORR in 3-4L; 67% landmark 6-month PFS rate; 33% unconfirmed ORR in 3L+ colorectal cancer; 43% confirmed ORR with 600 mg QD monotherapy in 2L+ non-small cell lung cancer; 2% discontinuation rate due to adverse eventsRead More | VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Calkins DanielOfficer (Chief Financial Officer) | Sell | -2,566 123,781 held | $8.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VSTM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.2 % (-33.3 %) | 25.35 M | 6.64 M | 0.9% ( 59.49 K) |
VSTM Institutional Ownership Trends
VSTM Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
15.0M
Shares Sold Short
-17.0% vs prior count
7.0 High
Days to Cover
trading days of normal volume to buy every short share back
2.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VSTM ranks across every disease it competes in
Competitive Position is a premium feature
See how VSTM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVSTM News
VSTM▲ +9.2%on this news
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology will report its third quarter 2026 financial results on November 5, 2026. The company will host a conference call and webcast at 4:30 pm ET to discuss these results and provide business updates. Investors can access the live audio webcast on the company's website.
Read more →VSTMVerastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology has announced the pricing of a $250 million underwritten offering of common stock and pre-funded warrants. The offering, priced at $8.00 per share, is expected to close on or about October 15, 2026. Proceeds will be used for clinical development and general corporate purposes. The offering is managed by Jefferies, Guggenheim Securities, and Cantor.
Read more →VSTMVerastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Verastem Oncology has appointed Michael P. Bailey as the new President and CEO, effective January 1, 2027, following the planned retirement of Daniel Paterson. Bailey, who has over 30 years of experience in the biopharmaceutical industry, will lead the company's commercial growth and clinical advancements, including the investigational drug VS-7375. Paterson will remain as an advisor and board member, contributing to the company's ongoing initiatives.
Read more →VSTMVS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Verastem Oncology announced promising results from the TARGET-D 101 Phase 1/2 trial of VS-7375, an oral KRAS G12D inhibitor. The drug demonstrated a 50% confirmed objective response rate (ORR) in second-line pancreatic ductal adenocarcinoma (PDAC) and achieved robust responses across multiple tumor types. The company plans to initiate a Phase 3 trial for first-line mPDAC by the end of 2026.
Read more →VSTMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology has announced the grant of 380,500 restricted stock units and stock options to new employees as part of its strategy to attract talent. This move is in line with the Nasdaq inducement grant exception, highlighting the company's commitment to enhancing its workforce. The grants are aimed at supporting the company's mission in developing treatments for RAS/MAPK pathway-driven cancers.
Read more →VSTMVerastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Verastem Oncology has announced new analyses from the RAMP 201 study, which demonstrate promising outcomes for the combination of Avutometinib and Defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC). These findings will be presented at the upcoming IGCS 2026 conference, showcasing the potential of this treatment approach.
Read more →VSTMVerastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology has published two-year median follow-up data from the RAMP 201 study in Gynecologic Oncology. The results highlight the durable clinical benefits and manageable safety profile of AVMAPKI® FAKZYNJA® in treating recurrent low-grade serous ovarian cancer. This reinforces the treatment's potential in this patient population.
Read more →VSTMVerastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem Oncology has announced a late-breaking oral presentation regarding its RAMP 201 study, focusing on molecular profiling and tumor biomarker analysis for low-grade serous ovarian cancer. This presentation will take place at the IGCS 2026 Annual Global Meeting, showcasing the company's advancements in cancer research. The findings could provide valuable insights into treatment strategies.
Read more →VSTMVerastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Verastem Oncology will present new clinical data for VS-7375, an oral KRAS G12D inhibitor, at an investor event on October 14. The data will focus on its efficacy and safety in treating pancreatic, lung, and colorectal cancers. This presentation is part of the ongoing TARGET-D clinical development program.
Read more →VSTM▲ +5.4%on this newsshared move
Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem Oncology has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. These events will provide the management team with opportunities to engage with investors and discuss advancements in their cancer treatment developments. The conferences are scheduled for early September 2023.
Read more →VSTM▲ +14%on this news
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology reported its financial results for Q2 2026, showcasing significant growth in its commercial business and pipeline programs. The company highlighted strong performance driven by new patient starts for its product AVMAPKI FAKZYNJA CO-PACK. This progress reflects Verastem's commitment to developing treatments for cancers driven by the RAS/MAPK pathway.
Read more →VSTMVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Verastem Oncology has successfully dosed the first patient in the TARGET-D 203 Phase 2 trial, which is focused on the oral KRAS G12D inhibitor, VS-7375. This trial aims to evaluate the efficacy of VS-7375 in treating patients with KRAS G12D-mutated metastatic colorectal cancer. The initiation of this trial marks a significant step in advancing treatment options for this specific cancer mutation.
Read more →VSTMVerastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Verastem Oncology has announced a conference call to report its financial results for the second quarter of 2026. The call is scheduled for August 6, 2026, at 4:30 pm ET. The event will include a live audio webcast and accompanying slides available for investors.
Read more →VSTMVerastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Verastem Oncology has successfully dosed the first patient in its TARGET-D 202 Phase 2 clinical trial. This trial is focused on evaluating the efficacy of VS-7375 in patients with KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC). The trial aims to provide insights into a promising treatment avenue for this challenging cancer type.
Read more →VSTM▼ -8.6%on this news
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Verastem Oncology announced positive preliminary data from the TARGET-D 101 Phase 1/2 clinical trial of VS-7375, an oral KRAS G12D inhibitor. The trial showed broad anti-tumor activity in advanced KRAS G12D-mutated solid tumors, including pancreatic, colorectal, and lung cancers. The drug demonstrated a favorable safety profile with manageable gastrointestinal side effects. Verastem plans to expand its development strategy, including combination therapies, and will provide further updates later this year.
Read more →VSTMVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology has announced positive updated results from the RAMP 205 study, which evaluated the combination of Avutometinib and Defactinib alongside standard chemotherapy for first-line treatment of metastatic pancreatic cancer. The findings indicate a promising efficacy of this combination therapy, potentially enhancing treatment options for patients.
Read more →VSTMVerastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Verastem Oncology has initiated the TARGET-D 201 Phase 2 trial by dosing the first patient with VS-7375, an oral KRAS G12D inhibitor. This trial aims to evaluate the efficacy of the treatment in patients with KRAS G12D-mutated metastatic pancreatic cancer. The study is registration-directed, indicating its importance in the drug approval process.
Read more →VSTMVerastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology is set to host an investor conference call to discuss updated data and progress on their VS-7375 oral KRAS G12D inhibitor within the TARGET-D clinical program. The event aims to provide insights into the ongoing developments and future directions of this therapeutic approach.
Read more →VSTMVerastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology is scheduled to present at the Jefferies Healthcare Conference. This event will provide an opportunity for the company to share insights and updates regarding its oncology pipeline. Further details about the presentation or specific topics to be discussed have not been disclosed.
Read more →About Verastem, Inc.
Headquarters117 KENDRICK STREET, NEEDHAM, MA, 02494
BIOPHARMAWATCH ELITE PLUS
Trade the next VSTM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime